At T12, we observed a clear reduction in the proportion of improved NAFLD treated patients compared to not treated NAFLD patients for ALT, γGT, CRP, TNF-α, Endocan, HMGB-1, and TBARS. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.